Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
196
resultados
Última actualización
16/11/2025 [06:50:00]
Resultados 100 a 125 de 196
Resumen de: CN120899751A
本发明公开了一种调节动脉粥样硬化病灶的纳米药物的制备方法及其产品和应用，属于医药化工领域，所述方法包括：制备巨噬细胞膜，通过纳米沉淀法制备得到植物多糖纳米粒子，所述植物多糖纳米粒子包括：聚乳酸‑羟基乙酸共聚物载体，聚乳酸‑羟基乙酸共聚物载体上载有植物多糖；使用巨噬细胞膜包被植物多糖纳米粒子。本发明制备方法简单，效果显著。
Resumen de: CN120904226A
本发明属于纳米医药技术领域，具体为一种雷西莫特前药、活性氧响应型雷西莫特前药纳米颗粒的制备方法及其抗肿瘤应用。将对羟甲基苯硼酸酯与丁二酸酐反应，得到苯硼酸酯‑丁二酸酐连接臂；将所述苯硼酸酯‑丁二酸酐连接臂与雷西莫特进行酯化反应，得到雷西莫特前药；将载体和雷西莫特前药混合，并加入水进行乳化，得到活性氧响应型雷西莫特前药纳米颗粒。通过苯硼酸酯‑丁二酸酐修饰雷西莫特，显著增强药物疏水性，同时利用苯硼酸酯键对活性氧(ROS)的特异性响应特性，实现药物在肿瘤部位的精准控释，显著提高抗肿瘤效果。
Resumen de: CN120899905A
本发明涉及抗肿瘤技术领域，具体涉及一种硼化锰光热纳米颗粒及其制备方法与应用。本发明以β‑环糊精、硼化锰为原料，通过高温碳化法合成具有光热效应的ICD诱导剂MnB@β‑CD；此ICD诱导剂在结合近红外光辐照下，能促进树突状细胞(DCs)的募集，增强对抗肿瘤效应T细胞的交叉激发。此外，此ICD诱导剂还具有良好的生物安全性，并将免疫疗法与光热疗法整合到同一平台。
Resumen de: CN120904227A
本发明属于医药材料合成和应用技术领域，涉及一种基于吩嗪‑氟硼吡咯杂化共轭的有机自由基光热剂及其制备方法和应用。所述的有机自由基光热剂的制备方法，包括如下步骤：（1）在第一溶剂存在条件下，将化合物1和酰化试剂混合，进行第一反应，得到的化合物2；（2）在第二溶剂存在条件下，将化合物2、化合物3、乙酸和哌啶混合，进行第二反应，得到所述有机自由基光热剂。本发明提供的基于吩嗪‑氟硼吡咯杂化共轭的有机小分子自由基光热剂，通过简单的官能团调控，即可实现在有机溶剂中强的短波红外吸收，最大吸收波长大于1000 nm。本发明的制备方法，合成方法简单、原料成本低、作用条件温和，通过两步工艺得到的目标产物。
Resumen de: CN120899665A
本发明公开了PLGA‑姜黄素纳米颗粒的制备方法与应用。本发明涉及生物医学技术领域，包括如下步骤：以聚乙烯醇(PVA)水溶液为水相，聚乳酸‑羟基乙酸共聚物(PLGA)和姜黄素(Cur)的二氯甲烷溶液为油相，采用水包油包水的双乳液法制备了包载姜黄素的PLGA纳米颗粒(PLGA@Cur NPs)，制备的PLGA纳米粒呈球形，颗粒大小均一，载体PLGA具有良好的生物相容性和生物降解性，无毒、无刺激，并且在纳米粒的制备过程无需加入表面活性剂，进一步降低了毒性。
Resumen de: CN120899625A
本发明公开了用于治疗椎间盘退行性疾病的双模态核酸清除系统及其制备与应用方法。使用髓核细胞膜囊泡包载小分子线粒体膜稳定剂，制备工程化纳米囊泡。与透明质酸溶液混合后，加入PAMAM树枝状聚合物，通过Schiff碱反应交联形成水凝胶，得到所述双模态核酸清除系统。其中，水凝胶通过正电荷结合组织间隙中释放的阴性cfDNA，高效清除组织微环境中的致炎核酸，抑制M1型巨噬细胞极化及炎性因子释放，改善局部免疫微环境。工程化纳米囊泡用于将小分子线粒体膜稳定剂靶向递送至髓核细胞内，抑制线粒体外膜通透性增加所引起的DNA外泄，恢复细胞稳态，延缓细胞功能退化，协同作用，从细胞内源头与组织外部环境两个层面抑制炎症反应。
Resumen de: CN120899664A
本发明公开了透明质酸工程化线粒体及其制备方法和应用，属于生物医药技术领域。该透明质酸工程化线粒体是通过对分离纯化的功能性线粒体表面进行透明质酸和三苯基磷修饰得到，结合了透明质酸的肝组织亲和性与炎症靶向能力，并利用三苯基磷实现透明质酸的锚定，能够实现对肝损伤区域的精准递送与功能修复，有效提高线粒体在对乙酰氨基酚(APAP)诱导肝损伤模型中的治疗效果，解决药物性肝损伤(如APAP诱导肝损伤)治疗中存在的靶向性差、稳定性低以及生物利用率不足等技术难题。该策略为药物性肝损伤(Drug‑induced liver injury,DILI)，特别是APAP相关性急性肝损伤的干预提供了新的思路和可行的技术路径，具有显著的临床转化潜力和应用前景。
Resumen de: CN120476207A
The present disclosure relates to the field of diseases caused by iron overload, such as homeostatic iron regulatory protein (HFE) hemopigmentation. In particular, the present disclosure provides a method for targeting, in the liver, c.845Ggt; c.845Ggt; c.845Ggt; c.845Ggt; c.845Ggt; oligonucleotides of RNA editing technology for deamination of A nucleotides to reduce iron overload.
Resumen de: JP2025166811A
【課題】肺炎および気管支炎を含む、ＲＳＶ感染誘導性の急性の気道の病気の処置および／または予防のための組成物を提供する。【解決手段】ＲＳＶに対する免疫応答を誘導するための組成物であって、呼吸器合胞体ウイルス（ＲＳＶ）融合タンパク質Ｆ（Ｆ）ポリペプチドをコードする少なくとも１つのオープンリーディングフレームを含むＲＮＡ分子を含む組成物が提供される。本開示は、脂質ナノ粒子中に製剤化されたＲＮＡ分子（ＲＮＡ－ＬＮＰ）を含む組成物にさらに関する。本開示は、肺炎および気管支炎を含む、ＲＳＶ感染誘導性の急性の気道の病気の処置および／または予防のための、ＲＮＡ分子、ＲＮＡ－ＬＮＰ、および組成物の使用にさらに関する。【選択図】なし
Resumen de: DE102024112307A1
Die Erfindung betrifft Kompositpartikel, umfassend einen Kern aus einer hydrophoben Phase, welche auch vernetzt sein kann, wobei der Kern an der Oberfläche geladen ist. Auf der Oberfläche des Kerns ist eine Lipiddoppelschicht angeordnet, welche den Kern umschließt. Diese Lipiddoppelschicht umfasst mindestens ein Lipid mit einer funktionellen Gruppe. Entsprechend funktionalisierte Kompositpartikel können zur Aktivierung von T-Zellen eingesetzt werden.
Resumen de: WO2025231432A1
The present disclosure provides methods and compositions for therapeutic use, where the methods and compositions include the use of the CRISPR complex. The CRISPR complex is used to perform therapeutic genome editing in vivo in somatic cells of an organism.
Resumen de: WO2025231114A1
Compounds are provided having the following Formula (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, and G1 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: US2025339514A1
In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and/or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer, a cationic lipid, or a combination thereof; an antigen disposed within or attached to said biocompatible polymer or a nucleic acid encoding said antigen, where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a targeting moiety that binds to a scavenger receptor in the liver.
Resumen de: WO2025228979A1
The present invention provides lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for in vivo therapeutic applications. The present formulation is specifically directed to compositions comprising ionizable lipids and a lipid, which comprises a quaternary ammonium group as a permanently charged lipid.
Resumen de: WO2025228859A1
The invention relates to composite particles comprising a core made of a hydrophobic phase, which can also be cross-linked, wherein the core is charged on the surface. A lipid double layer which surrounds the core is located on the surface of the core. Said lipid double layer comprises at least one lipid with a functional group. Correspondingly functionalized composite particles can be used to activate T cells.
Resumen de: WO2025229179A1
The present invention relates to the combination of a compound of formula (I) as described herein with an hypomethylating agent (HMA) for use for the prevention and/ or treatment of cancer, in particular acute myeloid leukemia (AML), and AML-related myeloid diseases. The present invention further relates to a pharmaceutical composition comprising a compound of formula (I) as described herein with an HMA.
Resumen de: WO2025228975A1
The present disclosure relates generally to nucleic acid-lipid particles, in particular functionalised nucleic acid-lipid particles, methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.
Resumen de: WO2025228668A1
Disclosed is an impingement method for manufacturing lipid nanoparticles (LNPs) using a jet impingement reactor having a substantially spheroidal reaction chamber and/or non-retracted nozzles, an organic lipid solution having a lipid concentration of at least 50 mg/mL and an aqueous solution, such as a buffered aqueous solution comprising an active ingredient, for example an oligonucleotide or polynucleotide. Also provided is a dispersion of LNPs which is obtainable by the method.
Resumen de: WO2025231483A2
The invention relates to proteins and nucleic acids for immunization regimens, in particular, immunogens that can prime rare bnAb precursor B cells and guide their maturation towards bnAbs capable of neutralizing diverse HIV strains, modifications thereof, and/or development of nanoparticles, and/or development of membrane-anchored immunogens, and methods of making and using the same. The invention also encompasses cell surface trimers that bind to the broadly neutralizing antibodies and/or nucleic acids encoding the same.
Resumen de: WO2025231217A1
The present invention provides a nanoparticle composition comprising a nanocarrier; a nucleic acid; and a therapeutic agent that binds to the nucleic acid, wherein the nucleic acid and the therapeutic agent form a complex, wherein the nanocarrier encapsulates the complex.
Resumen de: WO2025230962A1
Gene editing material transportation constructs consistent with embodiments of this disclosure are designed to enable transporting of proteins and large DNA segments to different cell types around the body including across the blood-brain barrier, for targeted delivery to a variety of intended cell types. The constructs include gene editing material-containing inner capsid structures surrounded by exosome structures. The exosome structures contain a plurality of first recombinant polypeptides including a tetraspanin, e.g., CD9, and photoreceptor cryptochrome 2 protein (CRY2) fusion protein, while the inner capsid structure contains a plurality of second recombinant polypeptides including an inner capsid protein, e.g., CA/ p24, and truncated CRY-interacting basic helix-loop-helix 1 protein (CIBN) fusion protein. The CRY2 and CIBN portions of the constructs are a light-based dimerization system that enable reversible association of the first and second recombinant polypeptides to selectively assemble inner capsid constructs into exosomes for export.
Resumen de: WO2025231358A1
Isolation and characterization of MNDP, lipid nanoparticles derived from Lepidium meyenii Walp (maca), are disclosed. MDNP sequestered and neutralized multiple pro-inflammatory cytokines and APPs in its protein corona to reveal a highly effective therapeutic strategy for managing severe inflammatory responses. Lipid nanoparticle compositions based on the lipidomic analysis of MNDP are disclosed. Methods for the prevention and treatment for inflammatory diseases such as sepsis are disclosed.
Resumen de: WO2025230906A1
The present disclosure relates to lipid nanoparticles and uses thereof for, e.g. delivery to the liver and/or treating liver-related disorders or diseases.
Resumen de: WO2025230341A1
The present invention provides a use of SQB-DNA nanostructures, prepared using DNA origami technology, for inducing differentiation into nerve cells or nerve cell regeneration, or treating nerve damage or neurological diseases. The present invention is the first instance of achieving nerve recovery through precise ligand presentation using DNA origami nanostructures, and the widespread use of SQB as a therapeutic drug for various types of nerve damage and neurological diseases requiring nerve regeneration is expected due to the provision of the present invention.
Nº publicación: WO2025229946A1 06/11/2025
Solicitante:
UNIV OF TSUKUBA [JP]
SHIMANE UNIV [JP]
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u7B51\u6CE2\u5927\u5B66,
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u5CF6\u6839\u5927\u5B66
Resumen de: WO2025229946A1
Disclosed are: a hydrophilic-hydrophobic diblock copolymer or a nano-sized polymeric micelle containing said hydrophilic-hydrophobic diblock copolymer, said copolymer containing a poly(branched amino acid) segment represented by formula AA in which R is a residue for forming leucine, isoleucine, or valine and m is an integer of 3-200, and a poly(ethylene glycol) segment represented by formula BB in which n is an integer of 5-1,000; and a use for said copolymer/micelle in improving athletic ability and the like. When the hydrophilic-hydrophobic copolymer or the polymeric micelle is administered to a mammal such as a human, an improvement in athletic ability is achieved which cannot be realized by using a corresponding low-molecular leucine, isoleucine, or valine.
BOPI
Sede Electrónica
